Use to compare prespecified methods with reported outcomes, not as a completed result. Check noncommercial reuse conditions and processing permissions.
A RESEARCH PROJECT IN PLANNING
What does human evidence show about adding metformin to tuberculosis treatment?
Map clinical outcomes, adverse events and drug interactions in published studies of adjunctive metformin for pulmonary TB. Separate trial evidence from observational associations. No treatment recommendations.
Help with this researchA clear question. A shared goal. Evidence people can check.
WHY WE ARE DOING THIS
Our vision
Metformin is already being studied as an adjunct to TB therapy. The published METRIF randomized trial did not demonstrate faster sputum culture conversion; secondary inflammation measures and pharmacokinetic reports address different questions. A useful evidence map would keep these endpoints distinct and show what remains uncertain. Existing reviews must be checked before deciding whether an updated map adds value.
WHAT WE WANT TO ACHIEVE
The goals of this project
- 01
Map comparative human studies of metformin added to active TB treatment, linking protocols and related reports.
- 02
Keep clinical outcomes separate from biomarkers and drug-exposure findings, preserving negative results and missing data.
- 03
Identify safety, drug-interaction and evidence gaps for a qualified research team to assess.
THE WORK, AND HOW WE CHECK IT
Our research plan
Published comparative human studies of adults receiving treatment for active pulmonary tuberculosis, with metformin added to a stated anti-TB regimen versus a stated comparator. Keep randomized and observational studies separate, stratify diabetes and HIV status, and record drug susceptibility and concurrent therapy. Link protocols, registrations, outcome reports and pharmacokinetic substudies to the same cohort. Exclude TB-prevention associations, animal experiments and docking predictions from the clinical-outcome table. Use aggregate published data with verified reuse permissions only. A TB clinician, clinical pharmacologist and methods reviewer must approve the draft protocol, source permissions and extraction template. Pilot ten reports or all eligible reports if fewer; use independent extractions and human adjudication for every quantitative field. Check existing reviews, registrations, study overlap, prespecified outcomes, bias and safety reporting before scaling.
THE PEOPLE BEHIND THE QUESTION
Research lead sought
Independent project proposal
Organizer information is supplied by the project team.
This is a draft research proposal. No researcher or institution has adopted it yet.
YOUR EFFORT, FOR THIS CAUSE
Help move this project forward.
Open this project’s contributor app to see its approved tasks and return your work to this research team. This installation is connected to this project only.
Open & install this project’s appInstallable web app · Works in a browser · Internet connection required
THE EVIDENCE WE START FROM
Starting sources
These references motivate the plan. They are not new findings or automatic permission to reuse a source.
The primary culture-conversion result did not establish faster conversion. Assess secondary endpoints separately and retrieve a permitted full text before extraction.
Link to the parent trial rather than treating participants as independent. Full-text availability does not establish permission to adapt or process it.
A more recent primary interaction study. Keep its population and pharmacokinetic endpoints separate from the METRIF efficacy trial.